Alcon and RxSight have entered a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses. The partnership combines RxSight's post-operative light-adjustable technology with Alcon's PCIOL optical designs to create a co-developed technology that enables surgeons to fine-tune visual outcomes after cataract surgery. Under the agreement, RxSight will receive a $60 million upfront payment and could earn up to an additional $140 million in development and regulatory milestone payments. Alcon will lead global commercialization, while RxSight will handle development and manufacturing and receive royalties on net sales.
Alcon AGAlcon gains access to RxSight's light-adjustable technology to develop adjustable PCIOLs.
Rxsight IncRxSight receives $60M upfront and up to $140M in milestones, plus royalties.